The U.S. healthcare system is complex and evolving. For AbbVie to be FutureFit in this environment, it is vital that our USMAx Strategy Team thoroughly comprehend the current and future state of the evolving U.S. healthcare space and market access channels. In 2021 a thorough internal and external benchmarking project, led by AbbVie’s USMAx Strategy Team, identified a key need to increase strategic input and integration of the U.S. Payer landscape into AbbVie’s early pipeline development. A key recommendation from the benchmarking project was to create a new USMAx Early Pipeline Strategy Team to lead USMAx strategy creation for early pipeline assets with the goal of developing future assets with greater focus on the U.S. Payer environment.
The Director, U.S. MAx Early Pipeline Oncology will lead the U.S. market access strategy development for early pipeline priority assets within the AbbVie Oncology portfolio. The role reports to the Director of U.S. MAx Early Pipeline team and reports into the Vice-President of U.S. Max Strategy. The Director U.S. Max Early Pipeline Oncology lead will help integrate the understanding of the complex U.S. health system to m consistently anticipate the needs of U.S. payers into early brand plan development. The ideal candidate will have a strong understanding of US private and public payer segments to bring the voice of U.S. payers to our early drug development process. The candidate can think strategically and critically and build strong and trusting relationships for cross functional influence and is able to fully and properly represent US Market Access in pipeline governance discussions. The Director will annually align with cross-functional colleagues in ASL, GCD and GMAP organizations to determine U.S. MAx prioritization for the AbbVie Oncology portfolio. The role will integrate within the AbbVie Pipeline Commercialization Model and be a core team member of the asset Brand Strategy and Value and Access Teams (VATs). The Director will also participate as needed within Asset Strategy Team discussions and provide leadership within other deliverable teams as needed. The ideal candidate should have a track record of building deep cross-functional stakeholder alignment, experience in U.S. payer marketing strategy development, and an understanding of the AbbVie Pipeline Commercialization Model.
Responsibilities:
· Lead U.S. market access strategy creation and integration within the AbbVie oncology portfolio, including early phase oncology solid tumor and hematology assets
· Work effectively in the AbbVie pipeline commercialization model (PCM), including core membership in brand strategy (BST) and value and access teams (VAT)
· Navigate the complex development processes used across the organization to coordinate early asset development especially through early Touchpoints of 1-7-5 focused on market access evidence requirements
· Provide U.S. MAx input into oncology business development opportunities
· Establish relationships with key internal stakeholders who drive early pipeline development and planning including Asset Strategy Leads, global commercial leaders (GCD and GMCO), Global Medical Affairs (GMA) and Global Market Access and Pricing (GMAP)
· Provide US MAx input into early pipeline and commercial development processes, including key governance meetings when needed (TASC, PCC, LMG)
· Coordinate support for oncology pipeline assets with current U.S. MAx managed markets team members to optimize asset coverage
· Create compelling U.S. integrated access strategies (IAS) to handoff to U.S. IBTs when formed
· Determine relevant future channels by asset-indication and focus development initiatives to meet the interests of relevant external payer stakeholders
· Contribute critical strategic thinking to inform access and pricing assumptions to create accurate, market driven LRP assumptions to optimize U.S. value of oncology pipeline assets.
· Partner with market analytics and business intelligence (MABI) and U.S. Pricing team members to identify analogs and establish early economically justifiable prices for pipeline assets
· Provide guidance and strategic input into dosing and delivery system development through deep understanding of private and public payer segments. Identify opportunities and threats that may significantly impact U.S. commercial opportunities for each asset’s lifecycle management
· Other duties include relationship management, opportunity identification, qualification, competitive positioning, and strategy development on emerging trends (e.g., gene therapy access)
· Works closely with U.S. MAx Strategy Group and U.S. Government Affairs to stay abreast of future market environment scenarios that may impact strategic development for oncology disease areas
· Work closely with internal U.S. MA functional teams including account management, payer marketing, MABI, MA strategy and Population Health teams
Qualifications:
• 8+ years of U.S. market access experience preferred, some global market access experience a plus
• Oncology experience strongly preferred with both hematology and solid tumor assets
• Experience building and launching U.S. market access strategies for oncology products is preferred
• Experience in managing market access strategy development for drugs with multiple indications is preferred to provide recommendations on optimal indication sequencing for the U.S. market
• Deep subject matter expertise in commercial and government payers is required, including knowledge of U.S. Medicare system (Part B, C and D) buy and bill coding and reimbursement, and ASP model
• Knowledge and experience with drugs requiring complex distribution including wholesalers, specialty distribution and GPOs
• Experience in leading primary and secondary payer research projects to inform payer insights, value drivers and channel strategy/flow of money
• Experience in developing key portions of go to market strategies including value proposition development, patient support and channel and access strategy development
• Deep understanding of how these go to market strategies impact resource needs and gross to net calculations for long-range planning
AbbVie is an equal opportunity employer including disability/vets. It is AbbVie’s policy to employ qualified persons of the greatest ability without discrimination against any employee or applicant for employment because of race, color, religion, national origin, age, sex (including pregnancy), physical or mental disability, medical condition, genetic information, gender identity or expression, sexual orientation, marital status, status as a disabled veteran, recently separated veteran, Armed Forces service medal veteran or active duty wartime or campaign badge veteran or a person’s relationship or association with a protected veteran, including spouses and other family members, or any other protected group status. We will take affirmative action to employ and advance in employment qualified minorities, women, individuals with a disability, disabled veterans, recently separated veterans, Armed Forces service medal veterans or active-duty wartime or campaign badge veterans. The Affirmative Action Plan is available for viewing in the Human Resources office during regular business hours.
Significant Work Activities: Continuous sitting for prolonged periods (more than 2 consecutive hours in an 8 hour day)
Travel: Yes, 10 % of the Time
Job Type: Experienced
Schedule: Full-time

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real... Read more